Información del artículo
El Texto completo está disponible en PDF
References
[1.]
D. Pathirana, A.D. Ormerod, P. Saiag, C. Smith, P.I. Spuls, A. Nast, et al.
European S3-guidelines on the systemic treatment of psoriasis vulgaris.
J European Acad Dermatol, 23 (2009), pp. 5-70
[2.]
C.H. Smith, A.V. Anstey, J.N. Barker, A.D. Burden, R.J. Chalmers, D.A. Chandler, et al.
British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009.
Br J Dermatol, 161 (2009), pp. 987-1019
[3.]
L. Puig, J.M. Carrascosa, E. Daudén, J.L. Sánchez-Carazo, C. Ferrándiz, M. Sánchez-Regaña, et al.
Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos.
Actas Dermosifiliogr, 100 (2009), pp. 374-401
[4.]
A. Nast, P.H. Spuls, A.D. Ormerod, N. Reytan, P.H. Saiag, C.H. Smith, et al.
A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: ‘AGREE-ing’ on a common base for European evidence-based psoriasis treatment guidelines.
J European Acad Dermatol, 23 (2009), pp. 782-787
[5.]
Nederlandse Vereniging voor Dermatologie en Venerologie (NVDV) and the Institute for Healthcare Improvement (CBO). Dutch guideline for the treatment of severe psoriasis (ultraviolet B, ultraviolet A in combination with oral psoralen, cyclosporin A, methotrexate and acitretin). Van Zuiden Communications. ISBN 90-76906-88-2 [cited April 4, 2010]. Available from: www.cbo.nl/Downloads/376/rl_psoriasis_2005.pdf.
[6.]
C.H. Smith, A.V. Anstey, J.N. Barker, A.D. Burden, R.J. Chalmers, D. Chandler, et al.
British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005.
Br J Dermatol, 153 (2005), pp. 486-497
[7.]
A. Nast, I.B. Kopp, M. Augustin, K.B. Banditt, W.H. Boehncke, M. Follmann, et al.
Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris.
J Dtsch Dermatol Ges, 5 (2007), pp. 1-119
[8.]
A.J. Blasco, P. Lázaro, C. Ferrándiz, A. García-Díez, D. Liso.
Eficiencia de los tratamientos biológicos en el tratamiento de la psoriasis moderada-grave.
Actas Dermosifiliogr, 100 (2009), pp. 792-803
[9.]
S.R. Feldman, G.G. Krueger.
Psoriasis assessment tools in clinical trials.
Ann Rheum Dis, 64 (2005), pp. ii65-ii78
[10.]
L. Puig, X. Bordas, J.M. Carrascosa, E. Daudén, C. Ferrándiz, J.M. Herranz, et al.
Documento de consenso sobre la evaluación y el tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.
Actas Dermosifiliogr, 100 (2009), pp. 277-286
[11.]
A.K. Brimhall, L.N. King, J.C. Licciardone, H. Jacobe, A. Menter.
Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: A meta-analysis of randomized controlled trials.
Br J Dermatol, 159 (2008), pp. 274-285
[12.]
J. Schmitt, Z. Zhang, G. Wozel, M. Meurer, W. Kirch.
Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.
Br J Dermatol, 159 (2008), pp. 513-526
[13.]
N. Bansback, S. Sizto, H. Sun, S. Feldman, M.K. Willian, A. Anis.
Efficacy of systemic treatments for moderate to severe plaque psoriasis: Systematic review and meta-analysis.
Dermatology, 219 (2009), pp. 209-218
[14.]
C.L. Leonardi, A.B. Kimball, K. Papp, N. Yeilding, C. Guzzo, Y. Wang, et al.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double- blind, placebo-controlled trial (PHOENIX 1).
Lancet, 371 (2008), pp. 1665-1674
[15.]
K. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, N. Yeilding, et al.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebocontrolled trial (PHOENIX 2).
Lancet, 371 (2008), pp. 1675-1684
[16.]
L. Puig, D. Barco, A. Alomar.
Treatment of psoriasis with anti-TNF drugs during pregnancy. Case report and review of the literature.
Dermatology, 220 (2010), pp. 71-76
[17.]
L. Dubertret, S. Chimenti, E. Christophers, E. Daudén, M. De Rie, C.E. Griffiths, et al.
Alice, Éloi, Magali and Robert: The lives of four patients with psoriasis and the therapeutic approach of eight European experts.
Br J Dermatol, 160 (2009), pp. 1-30
[18.]
A. Menter, S.R. Feldman, G.D. Weinstein, K. Papp, R. Evans, C. Guzzo, et al.
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
J Am Acad Dermatol, 56 (2007), pp. 31.e1-31.e15
[19.]
Available from: http://www.nhs.uk/Conditions/Psoriasis/Pages/NICE.aspx [cited November 27, 2009].
[20.]
Available from: http://guidance.nice.org.uk/TA180 [cited November 27, 2009].
Copyright © 2010. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
